OXiGENE Announces Publication In The Journal Science Of Results Showing Combination Therapy With Vascular Disrupting Agents (VDAs) And An Antiangiogenic Drug Markedly Suppresses Tumor Regrowth In An Animal Model

WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 21, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the publication of the results of a preclinical study evaluating the combination of vascular disrupting agents (VDAs) with an antiangiogenic drug to enhance suppression of tumor growth in mice, which appears in today's issue of the journal Science. Using an antiangiogenic drug, DC101 (ImClone Systems, Inc.), 24 hours prior to administration of either of OXiGENE's VDAs, Combretastatin-A4 phosphate (CA4P) or OXi-4503, resulted in markedly enhanced anti-tumor activity in the study.